SAHPRA Approves Pfizer’s Paxlovid COVID-19 Treatment
SAHPRA announced the registration of Paxlovid COVID-19 treatment, an anti-viral medicine manufactured by Pfizer, to treat COVID-19. This is a 5-day oral treatment for mild to moderate COVID-19 in adults who do not require supplemental oxygen and who are at increased risk for progression to severe COVID-19.
International sources provide guidelines regarding prescribing in liver and kidney disease as well as possible drug interactions including statin therapy, anticoagulation and some hormonal birth control treatments.
Recent Posts
Driving Economic Transformation through Brain Health Investment in Africa
The Johannesburg Communiqué from the Africa Task Force on Brain Health declares that investing in brain health is crucial, as it supports Africa’s economic transformation and Agenda 2063 goals while covering dementia, mental health, brain trauma, and substance abuse. This investment aligns with N...
NICE Endorses Natalizumab RRMS Treatment Expansion for Refractory Cases
NICE Expands Access to Natalizumab RRMS Treatment for Highly Active Cases
The National Institute for Health and Care Excellence (NICE) has issued final draft guidance recommending natalizumab RRMS treatment o...
Bausch Health’s Strategic Growth in Latin American Pharmaceuticals Through Cardiometabolic ...
Navigating Growth in Latin American Pharmaceuticals
In the Latin American pharmaceuticals sector, Bausch Health is strategically expanding its footprint under the leadership of Vice President Fernando Zarate. The company's operati...